These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6157946)

  • 1. Effects of encainide (MJ9067) on the ventricular fibrillation threshold in anesthetized dogs.
    Jaillon P; de la Rosa S; Griffin JC; Winkle RA; Harrison DC
    J Cardiovasc Pharmacol; 1980; 2(5):517-26. PubMed ID: 6157946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canine electrophysiology of encainide, a new antiarrhythmic drug.
    Sami M; Mason JW; Oh G; Harrison DC
    Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog.
    Dawson AK; Roden DM; Duff HJ; Woosley RL; Smith RF
    Am J Cardiol; 1984 Sep; 54(6):654-8. PubMed ID: 6475789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiologic effects of encainide following acute coronary occlusion in dogs.
    Ro JH; Gillon J; Kupersmith J
    J Cardiovasc Pharmacol; 1981; 3(3):532-40. PubMed ID: 6168834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
    Lu HR; Remeysen P; De Clerck F
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):132-6. PubMed ID: 7564354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic modeling of antiarrhythmic drug effects--application to 3-methoxy-O-demethyl encainide.
    Dorian P; Davy JM; Kates RE
    J Cardiovasc Pharmacol; 1986; 8(6):1217-22. PubMed ID: 2434749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic evaluation of encainide with use of monophasic action potential recording.
    Samuelsson RG; Harrison DC
    Am J Cardiol; 1981 Nov; 48(5):871-6. PubMed ID: 6795911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of encainide and its metabolites on energy requirements for defibrillation.
    Fain ES; Dorian P; Davy JM; Kates RE; Winkle RA
    Circulation; 1986 Jun; 73(6):1334-41. PubMed ID: 3084128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia.
    Roden DM; Dawson AK; Duff HJ; Woosley RL; Smith RF
    J Cardiovasc Pharmacol; 1984; 6(4):588-95. PubMed ID: 6206311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of metoprolol and lidocaine on the ventricular fibrillation threshold in the anesthetized dog.
    de Langen CD; Balke CW; Spear JF; Levine JH; Moore EN
    J Cardiovasc Pharmacol; 1988 Dec; 12(6):683-8. PubMed ID: 2467087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological effects of encainide (MJ9067) on canine subendocardial Purkinje fibers surviving infarction.
    King BW; Man RY
    J Cardiovasc Pharmacol; 1984; 6(4):547-54. PubMed ID: 6206306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
    Brooks RR; Finch SL
    Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of flecainide, encainide, and clofilium on ventricular refractory period extension by transcardiac shocks.
    Sweeney RJ; Gill RM; Steinberg MI; Reid PR
    Pacing Clin Electrophysiol; 1996 Jan; 19(1):50-60. PubMed ID: 8848377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of antiarrhythmic drugs on the ventricular fibrillation threshold.
    Euler DE; Scanlon PJ
    J Cardiovasc Pharmacol; 1988 Mar; 11(3):291-8. PubMed ID: 2452921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological effects of encainide and its metabolites in 11 patients.
    Libersa CC; Lekieffre JP; Caron JF; Poirier JM; Pladys AM; Kacet S; Kher AR
    J Cardiovasc Pharmacol; 1985; 7(6):1077-82. PubMed ID: 2418291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone--an experimental study.
    Tsagalou EP; Anastasiou-Nana MI; Charitos CE; Siafakas CX; Drakos SG; Ntalianis A; Terrovitis JV; Mavrikakis EM; Doufas A; Nanas JN
    Resuscitation; 2004 Apr; 61(1):83-9. PubMed ID: 15081186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrillatory efficacy of encainide, loracainide and ORG 6001 compared with lignocaine in isolated hearts of rabbits and guinea-pigs.
    Almotrefi AA; Baker JB
    Br J Pharmacol; 1981 Jun; 73(2):373-7. PubMed ID: 6786403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.